111, Inc. (NASDAQ:YI) Short Interest Update

111, Inc. (NASDAQ:YI) was the target of a large drop in short interest in the month of March. As of March 31st, there was short interest totalling 3,000 shares, a drop of 54.5% from the March 15th total of 6,600 shares. Based on an average daily trading volume, of 41,200 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.1% of the shares of the stock are short sold.

Hedge Funds Weigh In On 111

A number of hedge funds have recently added to or reduced their stakes in the stock. Napean Trading & Investment Co Singapore PTE Ltd purchased a new stake in 111 in the fourth quarter worth $245,000. JPMorgan Chase & Co. lifted its stake in 111 by 43,619.9% during the fourth quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company’s stock worth $191,000 after purchasing an additional 305,339 shares during the last quarter. Finally, FIL Ltd bought a new stake in shares of 111 during the 4th quarter valued at $450,000. Institutional investors and hedge funds own 21.32% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of 111 in a report on Tuesday, April 8th.

111 Trading Up 2.6 %

Shares of YI traded up $0.19 during mid-day trading on Friday, reaching $7.50. The company’s stock had a trading volume of 1,855 shares, compared to its average volume of 23,149. 111 has a 1-year low of $4.15 and a 1-year high of $14.10. The stock has a market cap of $64.14 million, a P/E ratio of -1.88 and a beta of 0.57. The business has a 50-day simple moving average of $8.28 and a two-hundred day simple moving average of $7.52.

111 (NASDAQ:YI) last posted its quarterly earnings results on Thursday, March 20th. The company reported ($0.04) earnings per share (EPS) for the quarter. The company had revenue of $527.14 million for the quarter.

About 111

111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.